Rucaparib Maintenance for Recurrent Ovarian Carcinoma: Update From ARIEL3
Posted: Tuesday, October 6, 2020
According to an article published in the Journal of Clinical Oncology, rucaparib maintenance treatment extended progression-free survival in patients with platinum-sensitive, recurrent epithelial ovarian carcinoma, without detrimental effects on patient health status. In a post hoc exploratory analysis of the phase III randomized ARIEL3 study, results supported the benefits of rucaparib in this patient population, even when accounting for toxicities.
Amit M. Oza, MD, of the Princess Margaret Cancer Centre, Toronto, and colleagues performed analyses of both quality-adjusted progression-free survival and quality-adjusted time without symptoms or toxicity in more than 500 patients. The mean quality-adjusted progression-free survival was significantly longer with rucaparib versus placebo in all patient cohorts, including the intention-to-treat population (6.28 months), BRCA-mutated cohort (9.37 months), homologous recombination–deficient (HLD) cohort (7.93 months), and BRCA wild-type/loss of heterozygosity–low patient subgroup (2.71 months). The mean quality-adjusted time without symptoms or toxicity also consistently favored rucaparib versus placebo, ranging from 3.35 months to 9.73 months.
Maintenance treatment with a PARP inhibitor such as rucaparib is often standard of care for patients with epithelial ovarian carcinoma after a response to chemotherapy. However, this study is reportedly the first to perform an analysis of quality-adjusted time without symptoms or toxicity for a PARP inhibitor in ovarian cancer and to report the quality-adjusted outcomes for a PARP inhibitor including patients with ovarian cancer without a known deleterious BRCA mutation.
“Health-related quality of life is of great importance to women with ovarian cancer because of the significant morbidity they experience as a result of the disease and its treatment,” the authors noted. “When weighted by patients’ perceptions of their health status, the progression-free survival benefit of rucaparib persisted.”
Disclosure: For full disclosures of the study authors, visit ascopubs.org.
